Home Meetings Directions About Us Sponsors Mailing List Links

SCDMDG presents:

The Use of BDDCS in Drug Development: The Observations, The Predictions, Understanding the Scientific Basis and The Extensions

Tuesday April 19, 2016
Les Benet, Ph.D.
Professor, Dept. of Bioengineering and Therapeutic Sciences
University of California
San Francisco, CA

Les Benet, PH.D.

About The Meeting

Dr. Benet will examine the utility of the Biopharmaceutics Classification System (BCS) and help you understand the interplay of drug metabolizing enzymes and transport proteins as it relates to bioavailability and hepatic elimination. Dr. Benet will discuss:

  • The Biopharmaceutics Classification System (BCS) - A system for predicting in vivo performance of drug products from in vitro measurements
  • Slight modifications of such a Classification system can be useful in predicting:
    • Routes of drug elimination
    • The effects of efflux and absorptive transporters on oral drug absorption
    • When transporter-enzyme interplay will yield clinically significant effects
    • Transporter effects on post-absorptive systemic drug concentrations
    • Drug-drug interaction potential via the relationship to enzyme-transporter interplay


Dr. Benet, Professor, Department of Biopharmaceutical Sciences, UCSF received honorary doctorates from eight universities. During 1986, Dr. Benet was a founder and first President of AAPS. In 1987 he was elected to membership in the Institute of Medicine of the U.S. National Academy of Sciences. His many awards include: AAPS Distinguished Pharmaceutical Scientist (1989); AACP Volwiler Research Achievement (1991); ASCPT Rawls-Palmer Award (1995); APhA Higuchi Research Prize (2000); AAPS Wurster Award in Pharmaceutics (2000); FIP Høst-Madsen Medal (2001). Dr. Benet is listed by Thompson Reuters as one of the most highly cited pharmacologists worldwide, with his published peer-reviewed papers cited more than 20,000 times. His most recent work has addressed the interplay of metabolic enzymes and transport proteins as related to oral bioavailability and hepatic elimination, and the development of the Biopharmaceutics Drug Disposition Classification System (BDDCS). PSWC Research Achievement and CRS Career Achievement in Oral Drug Delivery (2004). His research interests, more than 530 publications and 11 patents are in the areas of pharmacokinetics, biopharmaceutics, drug delivery and pharmacodynamics. In 2004, he was awarded the Pharmaceutical Sciences World Congress Research Achievement Award and the CRS Career Achievement in Oral Drug Delivery Award. In 2007 he was selected as the UCSF Distinguished Clinical Research Lecturer and is still the only non-MD so honored. In 2010, he received the ASCPT Hunter Memorial Award in Therapeutics and in 2011 the ACCP Distinguished Investigator award. In 2012, the September issue of PHARMACEUTICAL RESEARCH was dedicated in his honor under the title "50 Years of Scientific Excellence and Still Going Strong" and he was made an honorary member of FIP. In March 2013, he was awarded the APhA Ebert Prize and the September issue of JOURNAL OF PHARMACEUTICAL SCIENCES was dedicated in his honor. In October, 2015 Dr. Benet was awarded the ISSX Scientific Achievement Award. He presently serves on the Boards of Directors of the American Foundation for Pharmaceutical Education, Impax Laboratories, and Medicines360, of which the latter, he chairs.

Date:   Tuesday April 19, 2016 – 5:00 p.m. (Appetizers), 6:00 p.m. (Buffet Dinner), 7:00 p.m. (Presentation)
Location:   National University, North Building
11355 North Torrey Pines Road
La Jolla, CA 92037
Price:   $20 Registration in advance or at the door (includes appetizers, buffet dinner and beverages)

Space is Limited — Register Early to Guarantee Your Attendance!

Click here for a printable flyer.

Our April 2016 meeting is generously sponsored by:

Silver Sponsors

Oxford Biomedical Research
Oxford Biomedical Research
Sekisui Xenotech
Sekisui Xenotech

Bronze Sponsors

Agilux Laboratories
Agilux Laboratories

National University

National University

For more information on sponsoring our April meeting, please refer to our sponsorship guidelines.

Prior presentations:

Note: slides are displayed in a new window, left-click to advance, right-click to go back.

Speaker PDF Topic Date
Nicholas J. Schork, Ph.D.   Design and Implementation Issues in Clinical Trials Advancing Personalized Medicine September 15, 2015
Robert P. Hanzlik, Ph.D.   Reactive Metabolites, Cellular Targets and Beyond April 28, 2015
J. Ernest Simpson, Ph.D.   The Chemistry Of Wine October 28, 2014
Lawrence J. Marnett, Ph.D., F.C.P   Next Generation NSAIDs That Selectively Inhibit Endocannabinoid Metabolism by COX-2 May 6, 2014
Lawrence J. Lesko, Ph.D., F.C.P. Drug Interaction Studies: Differences and Similarities in How to Meet the Regulatory Expectations in FDA Guidance and EMA Guidelines May 14, 2013
Thomas Tozer, Ph.D.
Pharmacokinetics of Protein Drugs October 23, 2012
Shujuan Chen Application of Animal Models for Human Glucuronidation October 23, 2012
Caroline Decker The Use of Modified Bacterial CYPs for Metabolite Generation October 23, 2012
Mary Dwyer, Ph.D. Cancer Therapeutics: A Novel Approach October 23, 2012
Justin Hoffman PharmD MS Population Pharmacokinetics (PK) of LopinavirDuring Pregnancy and Postpartum October 23, 2012
David A. Yee Observations on the Urine Metabolic Ratio of Oxymorphone to Oxycodone in Pain Patients October 23, 2012
Nabil Hanna, Ph.D.   The Discovery and Development of Rituxan April 10, 2012
Dr. Richard Kim Drug Transporters: In Vitro and Knockout Model Systems, Pharmacogenomics, and Clinical Relevance April 19, 2011
Dr. Jerry Galluppi Biotherapeutic Drug Research and Development: A Growing Role for the DMPK Scientist October 5, 2010
Dr. Dennis Smith Does drug metabolism hold its future in its own hands? April 27, 2010
Dr. Paul F. Hollenberg Mechanism-Based Inactivation of Human Cytochromes P450 October 6, 2009
Dr. Jack H. Dean
Dr. Thomas Baillie
  Challenges & Opportunities in Drug Development from a Drug Safety and Metabolism Perspective May 19, 2009
Eric Johnson, Ph.D.   Characterization of Substrate/Inhibitor Binding to Drug-Metabolizing Cytochrome P450 Monooxygenases using X-ray Crystallography September 30, 2008
Dr. Kenneth E. Thummel, Ph.D.   Regulation Of Intestinal CYP3A By VDR: Implications And Safety Of Oral Therapeutics May 7, 2008
Dr. Anthony Lu, Ph.D.   Why Is The Liver Microsomal Cytochrome P450 Such A Versatile And Unique Enzyme? September 12, 2007
Dr. Scott Obach, Ph.D.   Leveraging ADME Data In Metabolites In Safety Testing (MIST) April 18, 2007
Dr. Sidney Nelson, Ph.D.   Drug Metabolism and Chemical Structural Alerts September 27, 2006
Richard B. Kim, MD   Relevance and Utility of Transporters to Drug Discovery and Development September 21, 2005
Dr. Frederick P. Guengerich, Ph.D.   Human Cytochrome P450 2A6 as a Case History:  Flavors, Smoke, Blue Roses, New Drugs & Basics of a P450 April 27, 2005
Dr. Leslie Benet, Ph.D.   Predicting Drug Disposition via Application of BCS: Transport/Absorption/Elimination Interplay and BDDCS September 29, 2004
Dr. Christopher A. Lipinski, Ph.D.   ADME/Tox: How Low Can You Go And How Do You Recover? April 21, 2004